Module 5: Lipid Management
Alan Chait, MD
- Pathophysiology & Vascular Biology
- Classification, Measurement and Metabolism of Lipids and Lipoproteins
- Cholesterol, lipoproteins, and ASCVD risk
Screening and Treatment of Hypercholesterolemia
Christie M. Ballantyne, MD; Maya Vadiveloo, PhD, RD; Pam R. Taub, MD
- ASCVD risk factors & risk enhancers
- Identification, testing and ASCVD risk assessment
- Lifestyle modifications for lipid lowering
- Pharmacologic treatment (current guidelines, efficacy and safety of statin and non-statin therapies)
Residual ASCVD Risk
Robert H. Eckel, MD
- Hypertriglyceridemia: Association or causative for ASCVD management
- HTG targets
- Review of HTG management strategies, from moderate to severe HTG
- HDL and HDL science/management
Other Players in Dyslipidemia (Optional/Not for Credit)
Sotirios Tsimikas, MD
- Lipoprotein (a) science/evidence/management, emerging therapies
The Foundations of Cardiometabolic Health Certification Course is appropriate for clinicians from a full spectrum of clinical experience including Physicians, Physician Assistants, Nurse Practitioners, Registered Nurses, Pharmacists, Diabetologists, and Dietitians who are in any phase of training, or even experienced physicians who are looking to take a deeper dive into cardiometabolic health.
After completing this activity, the participant should be better able to:
- List current and emerging treatment options for lipid lowering, including for hypercholesterolemia, hypertriglyceridemia, and elevated lipoprotein a.
- Recognize the burden of other lipid players beyond LDL-C in the development of atherosclerosis and residual ASCVD risk.
- Develop individualized treatment options for patients with dyslipidemia based on current treatment options and guideline recommendations.
Alan Chait MD
University of Washington
Dr. Chait discloses the following:
Consultant: Pfizer, LIB
Christie M. Ballantyne, MD
Professor of Medicine, Baylor College of Medicine
Professor, Molecular and Human Genetics
Professor, Molecular Physiology and Biophysics
Director, The Maria and Alando J. Ballantyne, M.D. Atherosclerosis Clinical Research Laboratory
Director, Center for Cardiometabolic Disease Prevention
Co-Director, Lipid Metabolism and Atherosclerosis Clinic
J. S. Abercrombie Chair - Atherosclerosis and Lipoprotein Research
Chief of Cardiology
Chief of Cardiovascular Research
Baylor College of Medicine
Dr. Ballantyne discloses the following:
Research Support (All paid to institution, not individual): Abbott Diagnostic, Akcea, Amgen, Esperion, Ionis, Novartis, Regeneron, Roche Diagnostic
Consultant: Abbott Diagnostics, Althera, Amarin, Amgen, Arrowhead, AstraZeneca, Corvidia, Denka Seiken, Esperion, Genentech, Gilead, Matinas BioPharma Inc, New Amsterdam, Novartis, Novo Nordisk, Pfizer, Regeneron, Roche Diagnostic, Sanofi-Synthelabo
Maya Vadiveloo, PhD RD FAHA
Assistant Professor of Nutrition and Food Sciences
University of Rhode Island
Dr. Vadiveloo has no relevant financial relationships to disclose.
Pam R. Taub MD, FACC
Founder and Director of Step Family
Cardiac Rehabilitation and Wellness Center
Professor of Medicine
UC San Diego Health System
Dr. Taub discloses the following:
Consultant: Sanofi, Novo-Nordisk, Novartis, Boehringer-Ingelheim, Bayer, Amarin Medtronic, Amgen, and Esperion
Stockholder: Epirium Bio
Research Support: NIH, Department of Homeland Security, Hillblom Foundation Network, AHA
Robert H. Eckel, MD, FAHA, FACC
Professor of Medicine, Emeritus
Division of Endocrinology, Metabolism and Diabetes
Division of Cardiology
S/P Charles A. Boettcher II Chair in Atherosclerosis
University of Colorado Anschutz Medical Campus
Dr. Eckel discloses the following:
Consultant: Amarin, Kowa, Kaleido, Novo Nordisk, Prevention Bio, The Healthy Aging Co., Weight Watchers
Sotirios Tsimikas, MD*
Director of Vascular Medicine
Professor of Medicine
University of California San Diego
Dr. Tsimikas discloses the following:
Royalty/Receipt of Intellectual Property Rights/Patent Holder: UCSD
Consulting/Contracted Research: Novartis
Stockholder: Kleanthi Dx, Oxitope Inc, Covicept Therapeutics
*Dr. Tsimikas' presentation is optional/not for credit
ESTIMATED TIME TO COMPLETE ACTIVITY
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING MEDICAL EDUCATION
Partners for Advancing Clinical Education designates this enduring material for a maximum of 6 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 6 contact hours. Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.
CONTINUING PHARMACY EDUCATION
Partners for Advancing Clinical Education designates this continuing education activity for 6 contact hour(s) (0.6 CEUs) of the Accreditation Council for Pharmacy Education.
This is an application-based activity. Universal Activity Numbers (UAN): JA4008073-9999-22-005-H01-P
For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.
CONTINUING DIETICIAN EDUCATION
This program offers 6 CPEUs for dieticians.
ABIM MOC CERTIFICATION
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6 MOC points in the American Board of Internal Medicine's (ABIM) maintenance of certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
MERIT-BASED INCENTIVE PAYMENT PROGRAM (MIPS)
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS).
DISCLOSURE OF CONFLICTS OF INTEREST
Partners for Advancing Clinical Education (PACE) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The PACE planners and others have nothing to disclose. The CMHC planners and others have nothing to disclose.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
METHOD OF PARTICIPATION & REQUEST FOR CREDIT
During the period March 11, 2022 through June 24, 2023, participants must read the learning objectives and faculty disclosures, study the educational activity, obtain a score of 75% or better on the post-test, and complete the evaluation. Upon completing, your certificate will be available for print. For questions about receiving certificates, please contact us at Foundations@cardiometabolichealth.org.
For questions about the accreditation of this activity, please visit www.clinicaleducationalliance.com.
For Pharmacists: Please complete the evaluation instructions above. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.
1) Complete this module post-test and evaluation.
2) Over the next 90 days, actively work to incorporate improvements in your clinical practice from these presentations.
3) Complete the follow-up survey from CMHC in approximately 90 days.
- 6.00 ABIM MOC and AMA PRA Category 1 Credit™
- 6.00 ACPE Pharmacy
- 6.00 AMA PRA Category 1 Credit™
- 6.00 ANCC
- 6.00 CDE
- 6.00 Participation
A computer with an internet connection
Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.